医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Blaze Bioscience Announces Poster Presentation at ASCO 2015 Annual Meeting

2015年05月27日 PM07:00
このエントリーをはてなブックマークに追加


 

SEATTLE & MELBOURNE, Australia

Blaze Bioscience, the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, and its subsidiary, Blaze Bioscience Australia Pty Ltd, announced today that the company’s Senior Vice President of Development, Dennis Miller, Ph.D., will present at the American Society of Surgical Oncology (ASCO) 2015 Annual Meeting, taking place in Chicago, IL on May 29-June 2, 2015.

The poster presentation, titled “Phase 1 dose escalation and expansion safety study of BLZ-100 in subjects with skin cancer,” will highlight the company’s first-in-human study.

Details of the poster presentation are as follows:

Trials in Progress Presentation
Date: Monday, June 1, 2015
Time: 1:15 PM – 4:45 PM CDT
Location: S Hall A
Poster Number: 324b
Abstract Number: TPS9084

About Tumor Paint BLZ-100

BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an Optide (optimized peptide), which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, enabling more precise, complete resection of cancer throughout surgery. Preclinical utility of Tumor Paint technology has been demonstrated in a wide range of cancer types, including brain, lung, breast, prostate, colorectal, and sarcomas. BLZ-100 is currently in Phase 1 proof-of-concept clinical studies to evaluate safety and imaging characteristics of BLZ-100 in solid tumor cancers.

About Blaze Bioscience

Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided cancer therapy. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital, and Heather Franklin, a former senior business executive from ZymoGenetics, and is working to develop Tumor Paint™ products and Optide-based guided cancer therapeutics. Surgery is first-line therapy for most solid tumor cancers and Tumor Paint products intend to improve cancer surgery by providing real-time, high-resolution visualization of cancer cells throughout surgery. The ability to see cancer cells in real time and high resolution throughout surgery should enable better detection and more complete and precise surgical removal of cancer—while sparing surrounding normal tissue. In addition to the Tumor Paint platform, Blaze is collaborating with the Fred Hutchinson Cancer Research Center to discover and develop guided cancer therapeutics as part of the Optides platform. This program extends the expertise gained in developing the Tumor Paint platform to optimized knottin peptide conjugates for therapeutic and imaging applications. For additional information, please visit www.blazebioscience.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150527005318/en/

CONTACT

Media:
Blaze Bioscience, Inc.
Lauren Nelson, 206-535-8144
lauren.nelson@blazebioscience.com
or
Investor
Relations:
SOS Communications LLC
Susan Specht Oram,
360-535-3035
spechtoram@gmail.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024